# US 2026/0097031 A1 · Opioid formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097031 A1
- Document ID: US20260097031A1
- Status: Published application
- Kind: A1
- Application number: 19/213,277
- Filed: 2025-05-20
- Published: 2026-04-09
- Earliest claimed: 2012-07-26
- Assignees: Camurus AB
- Applicants: Camurus AB
- Inventors: Fredrik Tiberg; Ian Harwigsson; Markus Johnsson
- Web page: https://patentgrep.com/patent/US20260097031A1

## CPC

- A61K 31/4748: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 1 2% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of treating opioid addiction in a patient, the method comprising administering to the patient a composition comprising:
about 35% by weight of buprenorphine;
about 14% by weight of phosphatidylcholine;
about 21% by weight of glycerol dioleate; and
about 30% by weight of N-methyl-2-pyrrolidone;
wherein the composition is administered once monthly, and
wherein the patient has previously received buprenorphine.

### Claim 32 (depends on 31)

The method of claim 31, wherein the patient has previously received sublingual buprenorphine.

### Claim 33 (depends on 31)

The method of claim 31, wherein the composition is administered from a pre-filled syringe.

### Claim 34 (depends on 31)

The method of claim 31, wherein the composition comprises about 40 mg to about 140 mg of buprenorphine (calculated as a free base).

### Claim 35 (depends on 31)

The method of claim 31, wherein the composition, after contact with an aqueous fluid, forms a liquid crystalline phase structure.

### Claim 36 (depends on 35)

The method of claim 35, wherein the liquid crystalline phase structure is a non-lamellar crystalline phase structure.

### Claim 37 (depends on 31)

The method of claim 31, wherein, the steady state variation between Cmax and Cmin concentration after administration cycle at steady state is no more than 20-fold.

### Claim 38 (depends on 31)

The method of claim 31, wherein, at steady state plasma concentrations, the Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/ml and 10 ng/ml after administration.

### Claim 39 (depends on 31)

The method of claim 31, wherein the composition has a viscosity that is about 1 to about 1000 mPas at 20° C. as measured with a CarriMed CSL 100 rheometer equipped with automatic gap setting.

### Claim 40 (depends on 33)

The method of claim 33, wherein the pre-filled syringe comprises a needle having a gauge greater than 20 G.

### Claim 41

A method of treating opioid dependence in a patient, the method comprising administering to the patient a composition comprising:
about 35% by weight of buprenorphine;
about 14% by weight of phosphatidylcholine;
about 21% by weight of glycerol dioleate; and
about 30% by weight of N-methyl-2-pyrrolidone
wherein the composition is administered once monthly, and
wherein the patient has previously received buprenorphine.

### Claim 42 (depends on 41)

The method of claim 41, wherein the patient has previously received sublingual buprenorphine.

### Claim 43 (depends on 41)

The method of claim 41, wherein the composition is administered from a pre-filled syringe.

### Claim 44 (depends on 41)

The method of claim 41, wherein the composition comprises about 40 mg to about 140 mg of buprenorphine (calculated as a free base).

### Claim 45 (depends on 41)

The method of claim 41, wherein the composition, after contact with an aqueous fluid, forms a liquid crystalline phase structure.

### Claim 46 (depends on 45)

The method of claim 45, wherein the liquid crystalline phase structure is a non-lamellar crystalline phase structure.

### Claim 47 (depends on 41)

The method of claim 41, wherein, at steady state plasma concentrations, the Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/mL and 10 ng/mL after administration.

### Claim 48 (depends on 41)

The method of claim 41, wherein the composition has a viscosity that is about 1 to about 1000 mPas at 20° C. as measured with a CarriMed CSL 100 rheometer equipped with automatic gap setting.

### Claim 49 (depends on 43)

The method of claim 43, wherein the pre-filled syringe comprises a needle having a gauge greater than 20 G.
